Last reviewed · How we verify
Pf-07985631 (pf-07985631)
At a glance
| Generic name | pf-07985631 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Mantle Cell Lymphoma
- Relapsed or Refractory Marginal Zone Lymphoma
- Relapsed or Refractory Follicular Lymphoma
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Relapsed or Refractory Waldenström Macroglobulinemia
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Relapsed or Refractory Hairy Cell Leukemia
- Relapsed or Refractory Graft-Versus-Host Disease
- Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Relapsed or Refractory Mycosis Fungoides
- Relapsed or Refractory Sézary Syndrome
- Relapsed or Refractory Peripheral T-Cell Lymphoma
- Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma
- Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder
- Relapsed or Refractory Kaposi Sarcoma
- Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia
- Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pentobarbital
- Phenobarbital
- Rivaroxaban
- Apixaban
- Dabigatran
- Clopidogrel
- Ticagrelor
- Prasugrel
- Cilostazol
- Dipyridamole
Key clinical trials
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07985631 CI brief — competitive landscape report
- Pf-07985631 updates RSS · CI watch RSS
- Pfizer portfolio CI